Ceftynet
Antibiotic
About
Ceftynet® is a brand of Cefixime, a third-generation cephalosporin antibiotic medication used to treat bacterial infections such as ear infections, bronchitis, pneumonia, urinary tract infections, gonorrhea, and other bacterial infections. Ceftynet® is a registered trademark of Carpa Healthcare limited.
Administration
Ceftynet® is available in capsule form and administered orally as recommended by a physician.
Pediatrics
Ceftynet® Tablets 400 mg are not recommended for use in children under 10 years old. The safety and efficacy of cefixime has not been established in children less than 6 months.
Adults
The recommended adult dosage of Ceftynet® is 400 mg daily according to the severity of infection, given either as a single dose or in two divided doses or as prescribed by a physician.
Elderly
Elderly patients may be given the same dose as recommended for adults. Renal function should be assessed and dosage should be adjusted in severe renal impairment
Side Effects
Ceftynet® may cause side effects. Inform your physician if any of these symptoms persist: Common side effects include diarrhea, abdominal pain, and nausea.
Prescription Information
Ceftynet is an orally active cephalosporin antibiotic which has marked in vitro bactericidal activity against a wide variety of Gram-positive and Gram-negative organisms. It is indicated for the treatment of the following acute infections when caused by susceptible micro-organisms: Upper Respiratory Tract Infections (URTI): e.g. otitis media; and other URTI where the causative organism is known or suspected to be resistant to other commonly used antibiotics, or where treatment failure may carry significant risk. Lower Respiratory Tract Infection: e.g. bronchitis. Urinary Tract Infections: e.g. cystitis, cyst urethritis, uncomplicated pyelonephritis. Clinical efficacy has been demonstrated in infections caused by commonly occurring pathogens including Streptococcus pneumoniae, Streptococcus pyogenes, Escherichia coli, Proteus mirabilis, Kliebsiella species, Haemophilus influenzae (beta-lactamase positive and negative), Branhamella catarrhalis (beta- lactamase positive and negative) and Enterobacter species.
